What is the difference between gene therapy and enzyme replacement therapy for rare inherited carbohydrate metabolism disorders?

The fundamental difference is that Enzyme Replacement Therapy (ERT) compensates for deficient or missing enzymes by supplying the body with manufactured enzymes, while gene therapy seeks to modify the genetic structure of cells to enable them to produce the missing enzyme themselves [4]. In inherited carbohydrate metabolism disorders, a defect occurs in the enzymes responsible for breaking down sugars, which leads to the accumulation of harmful substances [1].

Mechanism of Enzyme Replacement Therapy (ERT)

Enzyme replacement therapy relies on administering laboratory-manufactured enzymes to the patient to compensate for the deficiency in natural enzymes. For example, in Late-Onset Pompe Disease (LOPD), the drug POMBILITI (cipaglucosidase alfa-atga) is administered intravenously every two weeks and is used in combination with Opfolda, which is taken orally one hour before the infusion [5]. This treatment aims to help the body break down complex sugars that accumulate because natural enzymes are not functioning correctly [3]. This approach is a replacement therapy; the patient usually requires regular, ongoing doses to maintain sufficient enzyme levels and alleviate symptoms, as it does not address the underlying genetic cause [5].

Mechanism of Gene Therapy

Gene therapy aims to treat the root cause of a genetic disease by altering a person's genetic makeup. Instead of supplying the body with an external enzyme, a new gene is introduced into cells to fight the disease, or a healthy version of the gene is introduced to replace the defective version causing the disease [4]. When this process is successful, the body's cells begin producing the enzyme themselves, which could provide a long-term solution. Gene therapy is still under research and development for many disorders, with challenges regarding ensuring the precision of gene delivery, the safety of the process, and sustained gene expression [4]. It should be noted that hematopoietic stem cell transplantation is one of the therapeutic options for some conditions, such as alpha-mannosidosis, and it differs from direct gene therapy, which aims to modify genes within target cells [2].

Practical Differences and Considerations

These treatment options differ in several practical aspects:

• Availability: Enzyme replacement therapy is available and approved for some carbohydrate metabolism disorders, such as late-onset Pompe disease in adults who are not improving on current enzyme replacement therapy [5]. In contrast, gene therapy remains limited and is subject to extensive clinical trials for most genetic disorders [4].
• Continuity: Enzyme replacement therapy requires adherence to a schedule for periodic injections, usually every two weeks, as is the case with POMBILITI [5]. Gene therapy aims to achieve endogenous enzyme production, which could reduce the need for ongoing periodic interventions.
• Therapeutic Goals: Both aim to reduce the accumulation of harmful substances and alleviate organ damage. However, enzyme therapy treats the symptoms resulting from enzyme deficiency, while gene therapy targets the underlying genetic source of this deficiency [4].

To learn more about currently available options, you can review our detailed article on Inherited Carbohydrate Metabolism Disorders: Diagnosis and Treatment (Arabic). It is essential to consult a physician specializing in metabolic or genetic diseases to evaluate the individual case, as response to treatments varies based on the specific type of genetic mutation and the severity of clinical symptoms. Early intervention remains crucial, especially in cases that may lead to irreversible neurological or organ complications if not treated in a timely manner [3]. Symptoms must also be monitored closely, and any decline in physical or mental functions must be reported to the treating physician immediately.

Medical references

• What is gene therapy?: MedlinePlus Genetics
• Drug Trials Snapshots: POMBILITI | FDA
• Mucopolysaccharidoses
• Alpha-mannosidosis
• Carbohydrate Metabolism Disorders